Does the new drug Gleevec show promise?
Gleevec (imatinib mesylate), a drug developed to target the abnormal chromosome in chronic myelogenous leukemia (CML, another MPD), has been trialed in other MPDs, including PV. Initial trials have yielded mixed results, although a high proportion of those in the trials had a reduction in phlebotomy requirement. It appears not to help in lowering platelets, and the side effects can be significant (eg fluid retention – edema – diarrhea, nausea and fatigue). Trials are continuing.
